RxDoctor Payments Data

Leslie Busby, MD

Hematology & Oncology · Boulder, CONPI 1952385502

Payments from drug & device makers

$17,053in general payments, 2019–2025

Across 40 payments — averaging $426.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$12K
  • Pfizer$4K
  • Johnson & Johnson$346
  • Amgen$329
  • E.r. Squibb & Sons, L.L.C.$246
  • Caris MPI, Inc.$158
  • plus $945 from 11 others

What the payments were for

  • Consulting fees$13,25078%
  • Travel & lodging$1,6149%
  • Food & beverage$1,70510%
  • Education$4853%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,053 in reported general payments places this provider in the 45th percentile of 169 hematology & oncology providers in Colorado.

See all hematology & oncology providers in Colorado

Medicare billing

Part B allowed, 2024
$2,956,396
Medicare patients
471
Services billed
94,886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide38$895,073
RevlimidLenalidomide38$683,667
Lenalidomide27$399,393
VerzenioAbemaciclib31$363,314
BrukinsaZanubrutinib24$264,733
JakafiRuxolitinib Phosphate11$193,062
CalquenceAcalabrutinib Maleate25$180,365
XareltoRivaroxaban47$57,916
ZarxioFilgrastim-Sndz17$56,443
OrgovyxRelugolix19$48,670
EliquisApixaban48$45,223
Abiraterone Acetate31$40,932
Hydroxyurea42$1,942
Imatinib Mesylate13$1,433
Anastrozole88$1,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$246$895,07338 claims
Beigene USA, Inc.Brukinsa$156$264,73324 claims
AstraZenecaCalquence$11,512$180,36525 claims
Johnson & JohnsonXarelto$346$57,91647 claims
Sumitomo Pharma America, Inc.Orgovyx$20$48,67019 claims
PfizerEliquis$3,519$45,22348 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 169 hematology & oncology providers in Colorado.

Other hematology & oncology in Boulder

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →